We do not produce drugs, we are just porters in the international pharmaceutical market💊

Osimertinib ( #AZD9291 )
Origin: Bangladesh Incepta 
Non-small cell lung cancer: patients with metastatic non-small cell lung cancer, resistance to first-generation EGFR TKI targeted drugs, and epidermal growth factor receptor EGFR T790M mutation

We do not produce drugs, we are just porters in the international pharmaceutical market💊

Niranib
Efficacy: Suitable for maintenance treatment of adult patients with recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer who have completely or partially responded to platinum chemotherapy!

We do not produce drugs, we are just porters in the international pharmaceutical market💊


Targeted drugs, hope nothing is needed. Welcome to consult us for more global new drugs.

We do not produce drugs, we are just porters in the international pharmaceutical market💊

Lenvatinib, cabozantinib, olaparib, eltrombopag, palbociclib, venetoclax, gistrigen, trolagliptin, dasatinib, lapatinib, ibrutinib, osimertinib, crizotinib, erlotinib, brigatinib, tofacitinib, larotinib, doximetre, lenalidomide, tenofovir, abiraterone and other drugs💊 can provide direct mail service.

We do not produce drugs, we are just porters in the international pharmaceutical market💊

Alpelisib #PIK3CA#pivikto
150mg
[Indications] PIQRAY is a kinase inhibitor used in combination with fulvestrant FASLODEX for the treatment of postmenopausal women and men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer.

We do not produce drugs, we are just porters in the international pharmaceutical market💊

tucatinib
everest
Indications: Combination of #trastuzumab and #capecitabine for the treatment of adult patients with advanced unresectable or metastatic #HER2-positive breast cancer, including #brain metastases in patients who have received one or more prior anti-#HER2-based regimens in the metastatic setting

We do not produce drugs, we are just porters in the international pharmaceutical market💊

Modafinil, armodafinil, the best-selling wakefulness-promoting drugs

We do not produce drugs, we are just porters in the international pharmaceutical market💊


Vyvanse 20/50mg

We do not produce drugs, we are just porters in the international pharmaceutical market💊

JM Methylphenidate

We do not produce drugs, we are just porters in the international pharmaceutical market💊

Novartis Ritalin

We do not produce drugs, we are just porters in the international pharmaceutical market💊

Misoprostol
The common trade name is Cytotec, which is a synthetic PGE1 drug.

We do not produce drugs, we are just porters in the international pharmaceutical market💊

modafinil
Narcolepsy is a central nervous system disease of unknown cause. Its main symptom is the inability to maintain sleep during the day. Staying awake or alert, causing uncontrollable sleep attacks and cataplexy. Patients often suffer from inability to control sleep. And unable to live a normal life. Modafinil, as a new type of wake-up drug, can help patients get rid of drowsiness during the day. It can maintain normal work without any adverse reactions such as abnormal excitement, so it is known as the "God who never sleeps". The best drug to date for treating this sleep disorder.

We do not produce drugs, we are just porters in the international pharmaceutical market💊

We do not produce drugs, we are just porters in the international pharmaceutical market💊

We do not produce drugs, we are just porters in the international pharmaceutical market💊

【Pulmonary fibrosis】 Indian Grammark-Nedadanib nindanib 150, a box of 30 pills Nintedanib is a selective immunosuppressive drug that inhibits the proliferation, migration and transformation of fibroblasts by blocking intracellular signaling and exerting anti-fibrotic and anti-inflammatory activities.

We do not produce drugs, we are just porters in the international pharmaceutical market💊

Koselugo
Selumetinib is an orally available, selective, non-competitive ATP-active MEK1/2 inhibitor developed by AstraZeneca. It was approved by the US FDA in 2020. Selumetinib can reduce tumor size in children and adolescents with neurofibromatosis type I (NF1) genetic syndrome and improve symptoms such as pain and reduced mobility caused by plexiform neurofibromas caused by NF1. Target: MEK1/MEK2

We do not produce drugs, we are just porters in the international pharmaceutical market💊

Cabozantinib, a drug known as tiger balm, has actually been used to treat liver cancer, lung cancer, thyroid cancer, kidney cancer and other cancers for a long time. The overall efficiency is also very high. And now there are products like the Bangladeshi version, which are much more cost-effective.